General Announcement::Glenmark Pharmaceuticals receives ANDA approval for Fulvestrant Injection

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
23-Aug-2019 11:39:07
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals receives ANDA approval for Fulvestrant Injection
Announcement Reference
SG190823OTHRCCPS
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
23/08/2019 09:07:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)

Attachments

PR_SGX_23082019_signed.pdf
Total size =218K